VRS-317 is a novel, long-acting, recombinant human growth hormone, for the treatment of pediatric growth hormone deficiency. The Company has recently initiated a Phase 3 clinical study of VRS-317 in pediatric growth hormone deficient patients.

XTEN Technology

New compounds developed using the XTEN technology are expected to provide improvement in outcomes such as enhanced efficacy, fewer side effects, improved patient adherence and convenience, and enhanced stability.

Our Team

We are committed to building a first class organization to develop and commercialize VRS-317 and, most importantly, change the lives of people living with the burden of daily injection therapy for the replacement of hGH.

About Versartis

Versartis, Inc. is an endocrine-focused biopharmaceutical company initially developing novel, long-acting recombinant human growth hormone for the treatment of growth hormone deficiency.

Versartis is developing new therapeutic proteins utilizing the novel half-life extension technology, XTEN.


Latest News